高级检索
当前位置: 首页 > 详情页

Transforming Growth Factor-beta Promotes Homing and Therapeutic Efficacy of Human Mesenchymal Stem Cells to Glioblastoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Anesthesia,Wuhan,Hubei,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Neurosurg,Wuhan 430030,Hubei,Peoples R China [3]Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA [4]Univ Med Ctr Dusseldorf, Dept Neurosurg, Dusseldorf, Germany [5]German Canc Consortium DKTK, Partner Site Essen Dusseldorf, Dusseldorf, Germany [6]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Pediat,Wuhan,Hubei,Peoples R China [7]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Neurol,Wuhan,Hubei,Peoples R China
出处:
ISSN:

关键词: Glioblastoma Mesenchymal stem cells Therapeutic efficacy Transforming growth factor- (TGF-)

摘要:
Human mesenchymal stem cell-based tumor therapeutic gene delivery is regarded as a promising strategy for the treatment of glioblastoma (GBM). However, the efficiency of these stem cells to home to the target sites limits their potential curative effect and clinical application. In this work, we provide a novel pretreatment approach for enhancing the homing capacity of human adipose-derived mesenchymal stem cells (hAMSCs) for stem cell-based tumor gene delivery for GBM therapy. Pre-exposure of these stem cells to TGF- resulted in enhanced homing ability to GBM through increasing CXC chemokine receptor 4 (CXCR4) expression, as evidenced by a diminishing homing capacity when inhibition of the TGF- receptor II and CXCR4 was applied. In addition, by pretreating hAMSCs expression of tumor necrosis factor-related apoptosis-inducing ligand with TGF-, we achieved significant enhancements in the therapeutic efficacy as demonstrated by an increased number of migrated hAMSCs to target sites, decreased tumor volume, and prolonged survival time in a murine model of GBM. These findings highlight a straightforward method in which cell preconditioning methodology is utilized to promote therapeutic efficacy of a biological treatment for GBM.

基金:

基金编号: 81270865 2018CFB746 2017CFB171 03VP03791 AZ 95 464

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 2 区 病理学 3 区 临床神经病学 3 区 神经科学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 病理学 4 区 临床神经病学 4 区 神经科学
JCR分区:
出版当年[2017]版:
Q1 PATHOLOGY Q2 CLINICAL NEUROLOGY Q2 NEUROSCIENCES
最新[2023]版:
Q2 CLINICAL NEUROLOGY Q2 NEUROSCIENCES Q2 PATHOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Anesthesia,Wuhan,Hubei,Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:2 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)